常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.89/-1.45
|
|
企業價值
23.22M
|
| 資產負債 |
|
每股賬面淨值
-1.31
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
28.54M
|
|
每股收益
2.78
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/15 16:14 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. |

1.26 
